CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Egetis Recommends Public Cash Offer From ANI Pharmaceuticals

By Reuters News

Nov 5 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

  • EGETIS THERAPEUTICS: STATEMENT BY THE BOARD OF DIRECTORS OF EGETIS THERAPEUTICS IN RELATION TO THE PUBLIC CASH OFFER FROM ANI PHARMACEUTICALS

  • TOTAL VALUE OF OFFER AMOUNTS TO APPROXIMATELY SEK 5,304 MILLION

  • PRICE PER SHARE IN OFFER REPRESENTS A PREMIUM OF ABOUT 12.6% COMPARED TO CLOSING PRICE OF SEK 9.99

  • ANI PHARMACEUTICALS, ANNOUNCED PUBLIC CASH OFFER TO EGETIS' SHAREHOLDERS AND TO HOLDER OF CONVERTIBLE LOAN

  • SAYS TRANSACTION ENABLES EGETIS TO LEVERAGE ANI'S RARE DISEASE PLATFORM AND COMMERCIALIZATION CAPABILITIES

  • UNANIMOUSLY RECOMMENDS THAT SHAREHOLDERS OF EGETIS AND HOLDER OF CONVERTIBLE AND WARRANTS ACCEPT OFFER.

Further company coverage: EGTX.ST

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk